FDA BRIEFING BOOK WRITING SERVICES
BioBoston CRO provides FDA briefing book writing services for sponsors that need a clear, source-supported meeting package organized around defined objectives and questions. Support can cover the complete package, selected sections, an existing draft, cross-functional review, or independent quality control.
Global Reach
Therapeutic Area Coverage
Years of Experience
START A CONVERSATION
Select the support you need and share a few details about your project. We’ll use this information to route your inquiry to the appropriate BioBoston team member.
Please do not submit confidential, patient-identifiable, or proprietary information through this form.
The engagement should be scoped around the current state of the work, the intended decision or milestone, the source package, and the sponsor's approval responsibilities.
Translate approved meeting objectives, questions, positions, and evidence into a structured package that supports focused discussion.
Create one source map, content plan, responsibility model, and review process across regulatory, clinical, nonclinical, CMC, safety, statistics, and product functions.
Assess question quality, narrative logic, evidence support, cross-section consistency, open decisions, and milestone risk before redrafting.
when needed
Problems
The service is most valuable when the team can identify the specific control gap, decision, deliverable, or
recovery need rather than requesting generic capacity.
Scope
The exact scope depends on the maturity of the work, the quality of the inputs, the sponsor’s procedures,
the review model, and the target milestone.
Deliverables
Deliverables should be confirmed at kickoff and linked to defined sponsor decisions, review cycles, and downstream handoffs.
Client inputs
The sponsor does not need every detail finalized before kickoff, but approved decisions, open questions, source owners, reviewers, and deadlines must be distinguishable.
Process
1. Confirm the meeting context, objectives, questions, sponsor positions, source package, reviewers, milestone, and writing role.
2. Assess the approved strategy and sources; create the question map, outline, source map, authoring schedule, and open-item tracker.
3. Draft each issue narrative and evidence summary around the sponsor position, uncertainty, question, and specific feedback requested.
4. Coordinate cross-functional review and route unresolved scientific and regulatory decisions to designated owners.
5. Resolve comments, test alignment among questions and supporting content, and perform source and consistency quality checks.
6. Prepare clean, redline, approval, and submission-handoff versions and support meeting-preparation updates included in scope.
Considerations
The work should remain proportionate to the risk and intended use, follow the sponsor’s controlled process, and preserve clear sponsor decision authority.
Engagement options
BioBoston leads the defined scope from assessment and planning through drafting or execution, review, quality control, and handoff.
BioBoston addresses a specific section, decision, backlog, finding, vendor issue, or stalled deliverable without expanding the engagement unnecessarily.
BioBoston provides an objective second-line review, oversight role, or embedded specialist while the sponsor or another vendor retains primary execution.
RELATED SERVICES
Coordinate the meeting within the broader submission sequence, readiness plan, responsibilities, and regulatory milestones.
Define the pathway, classification, evidence implications, and regulatory decisions that shape the meeting strategy.
Connect meeting questions to the clinical development plan, protocol synopsis, endpoint strategy, vendor plan, and evidence roadmap.
Support design assumptions, sample size, endpoints, analysis concepts, evidence interpretation, and statistical questions included in the package.
Expertise
FDA briefing-book experience should match the meeting context, product type, development stage, technical issues, source complexity, and cross-functional review environment.
RESOURCES
Explore the following resources for additional insights and information relevant to this service.
A planned checklist for meeting objectives, questions, sponsor positions, sources, prior correspondence, responsibilities, review, and finalization.
A planned guide to decision scope, evidence support, specificity, requested feedback, and cross-functional approval.
A planned tool for question alignment, source support, narrative focus, consistency, prior commitments, and package readiness.
FAQs
Regulatory Affairs owns meeting strategy, meeting type, regulatory position, objectives, questions, and
authority planning. FDA Briefing Book Writing owns authoring and development of the package that communicates the approved strategy and evidence.
Yes. A focused engagement can cover specific issue narratives, data summaries, questions, background sections, or independent review if interfaces, sources, ownership, and the complete package strategy are clear.
Yes. The work should begin with an assessment of the meeting objective, questions, sponsor positions, source support, prior correspondence, comments, consistency, and remaining deadline.
Sources may include prior FDA correspondence, development plans, product and CMC documents, nonclinical and clinical reports, analyses, safety information, protocols, submissions, commitments, and approved meeting strategy materials.
Meeting-preparation support may be scoped separately or alongside writing, but the public page should distinguish package authoring from regulatory strategy, rehearsal, presentation, and meeting-lead responsibilities.
No. A well-developed package can improve clarity and readiness, but FDA determines its questions, discussion, and feedback, and the sponsor remains responsible for its positions and representations.
PROJECT FORM
Share the planned meeting or interaction, objectives, draft questions, product stage, current package status, prior FDA correspondence, review team, and target date. A BioBoston team member will review the request and follow up regarding fit and possible next steps.
Please do not submit confidential, patient-identifiable, or proprietary information through this form.
A productive first discussion identifies the meeting context, objectives, questions, sponsor positions, prior correspondence, evidence, reviewers, and deadline. BioBoston can then define the authoring scope, review model, and related regulatory and statistical support.
